RETA3 30mg
Triple agonist (GIP/GLP-1/glucagon) — 30mg vial for RETA3 research protocols.
Tap a strength to switch — price, image & stock update automatically
Key Benefits
simultaneously targets GIP, GLP-1, and glucagon receptors for synergistic metabolic effects no single agonist can match
Phase 2 trials showed 24.2% body weight loss at 48 weeks, the highest ever recorded for an injectable agent
addresses insulin resistance, dyslipidemia, and visceral fat accumulation through three complementary mechanisms
liver fat reduced by 81.7% from baseline in subgroup analysis, making it the most potent compound for fatty liver research
Active Signaling Pathway
Investigated Pathways
Proposed Mechanism
RETA3 (LY3437943) simultaneously agonizes GIP, GLP-1, and glucagon receptors via a single peptide backbone with a C20 fatty diacid modification for albumin binding and extended half-life (~6 days). The triple mechanism creates synergistic effects: GIP enhances insulin secretion and fat storage regulation, GLP-1 suppresses appetite and slows gastric emptying, and glucagon drives hepatic fat oxidation and thermogenesis.
Research Highlights
- Phase 2 NEJM 2023: 24.2% mean body weight reduction at 48 weeks — the highest ever reported for any injectable anti-obesity agent
- Liver fat reduced by 81.7% from baseline in NAFLD subgroup analysis
- Visceral adipose tissue reduced by 40%+ at maximum dose — exceeding dual agonists by a significant margin
- Phase 3 trials (TRIUMPH program) ongoing; FDA Breakthrough Therapy designation under review
Evidence is primarily from in vitro cell studies and animal models. Human data is limited or absent.
For laboratory research only
All Research Systems →Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
For research use only — not for human consumption. No treatment claims.
Full Research Hub →How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 30mg vial — and when to plan your next order.
Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.
Scientific Background
Mechanism of Action
RETA3 (LY3437943) simultaneously agonizes GIP, GLP-1, and glucagon receptors via a single peptide backbone with a C20 fatty diacid modification for albumin binding and extended half-life (~6 days). The triple mechanism creates synergistic effects: GIP enhances insulin secretion and fat storage regulation, GLP-1 suppresses appetite and slows gastric emptying, and glucagon drives hepatic fat oxidation and thermogenesis.
Clinical Context
The 15mg vial is designed for the full titration protocol, covering escalation from 1 mg through 8 mg and up to 12 mg/week maintenance — with enough peptide for 12+ weeks of dosing. At this dose range, RETA3 has demonstrated the most significant body composition changes of any peptide in its class. The 15mg vial covers months 2–5 of the protocol after tolerance is established with the 5mg starter vial.
Research Highlights
- Phase 2 NEJM 2023: 24.2% mean body weight reduction at 48 weeks — the highest ever reported for any injectable anti-obesity agent
- Liver fat reduced by 81.7% from baseline in NAFLD subgroup analysis
- Visceral adipose tissue reduced by 40%+ at maximum dose — exceeding dual agonists by a significant margin
- Phase 3 trials (TRIUMPH program) ongoing; FDA Breakthrough Therapy designation under review
Storage & Reconstitution
Store at -20°C. Reconstitute with bacteriostatic water (BAC water). Recommended: add 3 mL BAC water to the 15 mg vial → yields 5 mg/mL. On a 100-unit insulin syringe, 1 unit = 50 mcg; 20 units = 1 mg; 40 units = 2 mg; 80 units = 4 mg; 160 units (1.6 mL) = 8 mg; 240 units (2.4 mL) = 12 mg. Inject BAC water slowly down the vial wall — do not shake, gently swirl. Stable 28 days at 2–8°C. Do not freeze after reconstitution. Inject on the same day each week for consistent plasma levels.
Key Studies
Triple–Hormone-Receptor Agonist RETA3 for Obesity (Phase 2)
Jastreboff AM et al.
RETA3 12 mg/week produced 24.2% mean body weight reduction at 48 weeks — the highest ever reported for any injectable anti-obesity agent.
PubMed →RETA3, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
Rosenstock J et al.
RETA3 significantly reduced HbA1c and body weight in T2D patients with a manageable safety profile.
PubMed →Glucagon receptor contributes to the metabolic effects of triple agonism
Coskun T et al.
Glucagon receptor agonism in the triple agonist mechanism drives hepatic fat oxidation and energy expenditure beyond dual GIP/GLP-1 agonism.
Pharmacokinetics
Bioavailability indicates how much of the compound reaches systemic circulation. Peak plasma is when blood levels are highest. Half-life determines dosing frequency — compounds with short half-lives require more frequent dosing to maintain therapeutic levels.
The volume of distribution reflects how widely the compound distributes into tissues. A higher Vd means the compound concentrates in tissues rather than staying in plasma.
Receptor Binding Profile
Appetite suppression, insulin secretion, gastric emptying delay
Enhanced insulin secretion, adipocyte lipolysis, complementary metabolic effects
Hepatic fat oxidation, increased energy expenditure — unique triple mechanism
Synergistic satiety signaling from three receptor pathways
Side Effects & Adverse Events
- Nausea (45%)
- Vomiting (25%)
- Diarrhea (20%)
- Constipation
- Injection site reactions
- Tachycardia (glucagon receptor effect)
- Fatigue
- Pancreatitis (rare)
- Gallbladder disease
- Thyroid C-cell tumors (rodent data)
Contraindications & Interactions
Synergistic Compounds
Lipotropic support and B12 repletion during aggressive caloric restriction from triple agonist therapy.
Lipo-C 1 mL IM 2–3× per week alongside weekly reta3 injection.
View Compound →NAD+ supports mitochondrial function and energy metabolism during the significant metabolic shifts induced by triple agonism.
NAD+ 250 mg SubQ 2–3× per week during reta3 protocol.
View Compound →Transparent Global Sourcing
Manufactured
Sourced through our manufacturing partner in China
Independent Testing
Analytical reports available from Janoshik Analytical
Batch Verification
Batch-specific COAs with online verification via janoshik.com
US Fulfillment
Orders fulfilled from the United States